Agilent Technologies Inc. (NYSE: A) today announced that Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder ...

What Happened: Soriot made a significant move by purchasing 1,677 shares of Agilent Technologies as reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction's ...

Pascal Soriot has led AstraZeneca as CEO since 2012, guiding the company’s transformation into a global leader in science-driven innovation with a strong pipeline and substantial growth.

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

The Prostate Cancer Foundation (PCF) announced the recipients of its 2024 Challenge Awards, funding over $16 million in innovative prostate cancer research for cross-disciplinary, multi-institutional ...

Pascal Soriot said innovation in pharmaceuticals ‘has mostly been funded by the US’ as he doubled down on plans to grow the business in America – which already accounts for 40 per cent of ...

CompQsoft Digital, a global Microsoft solutions and services provider, today announced the appointment of Greg Moser as President and Board Member. Moser joins the leadership team, bringing over 30 ...

Sir Pascal Soriot is usually several steps ahead of the game, so always worth listening to. His latest red flag is that Europe is falling behind in healthcare innovation and manufacturing ...

Sir Pascal Soriot, AstraZeneca’s chief executive, said governments could “decide to not spend” on new medicines, but “then the jobs and the investments will go elsewhere”. He said ...

Delivering the main report Ajitha, a senior nurse in Dorset, England began by condemning the anti-immigrant measures ...

Harvey Jones says investment brokers showed their love for AstraZeneca shares at the start of the year, but maybe wondering ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...